Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy
Sung Ouk Nam1, Fusanori Yotsumoto1, Kohei Miyata1
1Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Background/Aim:
Heparin-binding epidermal growth factor-like growth factor (HB-EGF), which belongs to the epidermal growth factor family, is a rational therapeutic target for triple-negative breast cancer (TNBC). This study aimed to assess the anti-tumor efficacy of intravenous (i.v.) HB-EGF-specific inhibitor (CRM197) for TNBC.
Materials And Methods:
NOD/SCID mice were subcutaneously injected withTNBC cells, MDA-MB-231, and, then, treated with i.v. CRM197 in either dose- or frequency-dependent manners, using an advanced cancer model and an adjuvant therapy model. Tumor volume and mouse body weight were calculated weekly. Statistical significance was assessed by the Mann-Whitney U-test.
Results:
Mice that received i.v. CRM197 showed a significant anti-tumor effect in dose- and frequency-dependent manners in both models. However, their body weight did not differ significantly among groups.
Conclusion:
These results suggest that i.v. CRM197 is an effective treatment for TNBC.
